At present, the success of immunotherapy for primary and secondary brain tumors appears to depend on enhancing tumor-specific CD8+ T cell immunity since CD8+ T cells are strongly associated with direct tumor killing, and thus patient survival26–28. Here, CD8A is linked to neoplasm.